The momentum behind GLP-1 receptor agonists has become impossible to ignore. Originally developed to control blood glucose in diabetes, these therapies have surged to the forefront of obesity care, ...

Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...

Experts have issued GPs with crucial guidance on weight loss jabs to avoid deadly complications, as the injections are ...